Biotechnology Value Fund L P - Net Worth and Insider Trading

Biotechnology Value Fund L P Net Worth

The estimated net worth of Biotechnology Value Fund L P is at least $1.0 Billion dollars as of 2024-11-05. Biotechnology Value Fund L P is the of Kymera Therapeutics Inc and owns about 5,054,898 shares of Kymera Therapeutics Inc (KYMR) stock worth over $238 Million. Biotechnology Value Fund L P is the of Xenon Pharmaceuticals Inc and owns about 3,049,626 shares of Xenon Pharmaceuticals Inc (XENE) stock worth over $127 Million. Biotechnology Value Fund L P is also the of Cullinan Therapeutics Inc and owns about 7,415,823 shares of Cullinan Therapeutics Inc (CGEM) stock worth over $118 Million. Besides these, Biotechnology Value Fund L P also holds XOMA Royalty Corp (XOMA) , Olema Pharmaceuticals inc (OLMA) , ChemoCentryx Inc (CCXI) , MoonLake Immunotherapeutics (MLTX) , Repare Therapeutics Inc (RPTX) , Alpine Immune Sciences Inc (ALPN) , Cytokinetics Inc (CYTK) , Eledon Pharmaceuticals Inc (ELDN) , CTI BioPharma Corp (CTIC) , Arqule Inc (ARQL) , Merus NV (MRUS) , IDEAYA Biosciences Inc (IDYA) , Rain Oncology Inc (RAIN) , Five Prime Therapeutics Inc (FPRX) , Immune Design Corp (IMDZ) , Third Harmonic Bio Inc (THRD) , Concert Pharmaceuticals Inc (CNCE) , GlycoMimetics Inc (GLYC) , Pieris Pharmaceuticals Inc (PIRS) , Capstone Holding Corp (CAPS) , Calithera Biosciences Inc (CALA) , Infinity Pharmaceuticals Inc (INFIQ) , POINT Biopharma Global Inc (PNT) . Details can be seen in Biotechnology Value Fund L P's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Biotechnology Value Fund L P has not made any transactions after 2024-10-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Biotechnology Value Fund L P

To

Biotechnology Value Fund L P Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Biotechnology Value Fund L P owns 52 companies in total, including Five Prime Therapeutics Inc (FPRX) , Eledon Pharmaceuticals Inc (ELDN) , and XOMA Royalty Corp (XOMA) among others .

Click here to see the complete history of Biotechnology Value Fund L P’s form 4 insider trades.

Insider Ownership Summary of Biotechnology Value Fund L P

Ticker Comapny Transaction Date Type of Owner
FPRX Five Prime Therapeutics Inc 2020-11-11 10 percent owner
ELDN Eledon Pharmaceuticals Inc 2023-05-05 other: See Explanation of Responses
XOMA XOMA Royalty Corp 2023-01-06 other: See Explanation of Responses
LIMIT LIMIT 2021-10-08 other: See Explanation of Responses
LIMIT LIMIT 2023-11-03 other: See Explanation of Responses
LIMIT LIMIT 2020-08-18 other: See Explanation of Responses
LIMIT LIMIT 2021-02-02 other: See Explanation of Responses
LIMIT LIMIT 2020-05-21 other: See Explanation of Responses
LIMIT LIMIT 2022-08-09 other: See Explanation of Responses
LIMIT LIMIT 2020-12-09 other: See Explanation of Responses
LIMIT LIMIT 2019-09-06 other: See Explanation of Responses
LIMIT LIMIT 2020-11-04 other: See Explanation of Responses
LIMIT LIMIT 2019-06-10 other: See Explanation of Responses
LIMIT LIMIT 2021-02-11 other: See Explanation of Responses
LIMIT LIMIT 2018-12-04 other: See Explanation of Responses
LIMIT LIMIT 2017-11-28 other: See Explanation of Responses
LIMIT LIMIT 2018-05-30 other: See Explanation of Responses
LIMIT LIMIT 2017-08-15 other: See Explanation of Responses
LIMIT LIMIT 2017-11-17 other: See Explanation of Responses
LIMIT LIMIT 2017-07-14 10 percent owner & other: Direct Beneficial Owner
LIMIT LIMIT 2017-06-20 other: See Explanation of Responses
LIMIT LIMIT 2016-06-23 10 percent owner
LIMIT LIMIT 2015-11-04 other: See Explanation of Responses
LIMIT LIMIT 2009-07-09 other: Direct Beneficial Owner
LIMIT LIMIT 2008-11-06 10 percent owner & other: Direct Beneficial Owners
LIMIT LIMIT 2014-03-21 other: See Explanation of Responses
LIMIT LIMIT 2011-10-05 other: See Explanation of Responses
LIMIT LIMIT 2013-05-01 other: See Explanation of Responses
LIMIT LIMIT 2008-02-20 10 percent owner & other: Direct Beneficial Owner
LIMIT LIMIT 2009-12-22 other: Direct Beneficial Owner
LIMIT LIMIT 2009-12-18 10 percent owner
LIMIT LIMIT 2009-10-21 other: Direct Beneficial Owner
LIMIT LIMIT 2008-10-23 10 percent owner & other: Indirect Beneficial Owners
LIMIT LIMIT 2009-05-15 10 percent owner & other: Group Member
LIMIT LIMIT 2009-02-03 10 percent owner & other: Indirect Beneficial Owners
LIMIT LIMIT 2006-06-06 10 percent owner & other: Indirect Beneficial Owner
LIMIT LIMIT 2006-01-12 other: Direct Beneficial Owner
LIMIT LIMIT 2004-07-07 other: Direct Beneficial Owner
LIMIT LIMIT 2003-10-27 other: Direct Beneficial Owner
LIMIT LIMIT 2017-02-10 other: See Explanation of Responses
LIMIT LIMIT 2020-12-18 other: See Explanation of Responses
LIMIT LIMIT 2022-01-25 other: See Explanation of Responses
LIMIT LIMIT 2022-11-08 other: See Explanation of Responses
LIMIT LIMIT 2023-09-12 10 percent owner
LIMIT LIMIT 2022-06-01 other: See Explanation of Responses
LIMIT LIMIT 2023-11-16 other: See Explanation of Responses
LIMIT LIMIT 2024-10-04 director & 10 percent owner
LIMIT LIMIT 2022-06-16 other: See Explanation of Responses
LIMIT LIMIT 2022-07-11 10 percent owner
LIMIT LIMIT 2024-10-29 other: See Explanation of Responses
LIMIT LIMIT 2023-02-03 other: See Explanation of Responses
LIMIT LIMIT 2023-12-18 other: See Explanation of Responses

Biotechnology Value Fund L P Latest Holdings Summary

Biotechnology Value Fund L P currently owns a total of 26 stocks. Among these stocks, Biotechnology Value Fund L P owns 5,054,898 shares of Kymera Therapeutics Inc (KYMR) as of November 3, 2023, with a value of $238 Million and a weighting of 23.6%. Biotechnology Value Fund L P owns 3,049,626 shares of Xenon Pharmaceuticals Inc (XENE) as of August 15, 2017, with a value of $127 Million and a weighting of 12.62%. Biotechnology Value Fund L P also owns 7,415,823 shares of Cullinan Therapeutics Inc (CGEM) as of June 1, 2022, with a value of $118 Million and a weighting of 11.7%. The other 23 stocks XOMA Royalty Corp (XOMA) , Olema Pharmaceuticals inc (OLMA) , ChemoCentryx Inc (CCXI) , MoonLake Immunotherapeutics (MLTX) , Repare Therapeutics Inc (RPTX) , Alpine Immune Sciences Inc (ALPN) , Cytokinetics Inc (CYTK) , Eledon Pharmaceuticals Inc (ELDN) , CTI BioPharma Corp (CTIC) , Arqule Inc (ARQL) , Merus NV (MRUS) , IDEAYA Biosciences Inc (IDYA) , Rain Oncology Inc (RAIN) , Five Prime Therapeutics Inc (FPRX) , Immune Design Corp (IMDZ) , Third Harmonic Bio Inc (THRD) , Concert Pharmaceuticals Inc (CNCE) , GlycoMimetics Inc (GLYC) , Pieris Pharmaceuticals Inc (PIRS) , Capstone Holding Corp (CAPS) , Calithera Biosciences Inc (CALA) , Infinity Pharmaceuticals Inc (INFIQ) , POINT Biopharma Global Inc (PNT) have a combined weighting of 52.08% among all his current holdings.

Latest Holdings of Biotechnology Value Fund L P

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KYMR Kymera Therapeutics Inc 2023-11-03 5,054,898 47.07 237,934,049
XENE Xenon Pharmaceuticals Inc 2017-08-15 3,049,626 41.70 127,169,404
CGEM Cullinan Therapeutics Inc 2022-06-01 7,415,823 15.90 117,911,586
XOMA XOMA Royalty Corp 2023-01-06 3,645,542 30.86 112,501,426
OLMA Olema Pharmaceuticals inc 2023-09-12 8,897,173 11.86 105,520,472
CCXI ChemoCentryx Inc 2015-11-04 1,251,914 51.99 65,087,009
MLTX MoonLake Immunotherapeutics 2024-10-04 1,287,768 46.40 59,752,435
RPTX Repare Therapeutics Inc 2023-11-16 10,166,943 3.59 36,499,325
ALPN Alpine Immune Sciences Inc 2017-06-20 507,040 64.97 32,942,389
CYTK Cytokinetics Inc 2020-12-09 463,244 51.48 23,847,801
ELDN Eledon Pharmaceuticals Inc 2023-05-05 4,288,005 4.83 20,711,064
CTIC CTI BioPharma Corp 2022-08-09 2,271,791 9.09 20,650,580
ARQL Arqule Inc 2018-05-30 771,305 20.00 15,426,100
MRUS Merus NV 2021-10-08 232,747 51.23 11,923,629
IDYA IDEAYA Biosciences Inc 2021-02-02 233,150 30.00 6,994,500
RAIN Rain Oncology Inc 2022-11-08 3,288,186 1.21 3,978,705
FPRX Five Prime Therapeutics Inc 2020-11-11 81,263 38.00 3,087,994
IMDZ Immune Design Corp 2018-12-04 370,391 5.85 2,166,787
THRD Third Harmonic Bio Inc 2024-10-29 176,692 12.10 2,137,973
CNCE Concert Pharmaceuticals Inc 2019-06-10 169,589 8.37 1,419,460
GLYC GlycoMimetics Inc 2020-11-04 630,453 0.41 258,486
PIRS Pieris Pharmaceuticals Inc 2019-09-06 3,927 16.98 66,690
CAPS Capstone Holding Corp 2017-07-14 2,268 3.20 7,258
CALA Calithera Biosciences Inc 2020-05-21 24,022 0.01 168
INFIQ Infinity Pharmaceuticals Inc 2021-02-11 534,847 0.00 0
PNT POINT Biopharma Global Inc 2023-12-18 0 12.50 0

Holding Weightings of Biotechnology Value Fund L P


Biotechnology Value Fund L P Form 4 Trading Tracker

According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 8 transactions in Kymera Therapeutics Inc (KYMR) over the past 5 years, including 8 buys and 0 sells. The most-recent trade in Kymera Therapeutics Inc is the acquisition of 414,105 shares on November 3, 2023, which cost Biotechnology Value Fund L P around $5 Million.

According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 0 transactions in Xenon Pharmaceuticals Inc (XENE) over the past 5 years. The most-recent trade in Xenon Pharmaceuticals Inc is the acquisition of 60,202 shares on August 15, 2017, which cost Biotechnology Value Fund L P around $157,127.

According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 3 transactions in Cullinan Therapeutics Inc (CGEM) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Cullinan Therapeutics Inc is the acquisition of 751,396 shares on June 1, 2022, which cost Biotechnology Value Fund L P around $8 Million.

More details on Biotechnology Value Fund L P's insider transactions can be found in the Insider Trading History of Biotechnology Value Fund L P table.

Insider Trading History of Biotechnology Value Fund L P

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Biotechnology Value Fund L P Trading Performance

GuruFocus tracks the stock performance after each of Biotechnology Value Fund L P's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Biotechnology Value Fund L P is 30.17%. GuruFocus also compares Biotechnology Value Fund L P's trading performance to market benchmark return within the same time period. The performance of stocks bought by Biotechnology Value Fund L P within 3 months outperforms 55 times out of 106 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Biotechnology Value Fund L P's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Biotechnology Value Fund L P

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
62 out of 102 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 11.16 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 10.08 LIMIT LIMIT LIMIT LIMIT LIMIT

Biotechnology Value Fund L P Ownership Network

Ownership Network List of Biotechnology Value Fund L P

No Data

Ownership Network Relation of Biotechnology Value Fund L P

Insider Network Chart

Biotechnology Value Fund L P Owned Company Details

What does Five Prime Therapeutics Inc do?

Who are the key executives at Five Prime Therapeutics Inc?

Biotechnology Value Fund L P is the 10 percent owner of Five Prime Therapeutics Inc. Other key executives at Five Prime Therapeutics Inc include 10 percent owner Bvf Partners L P/il , 10 percent owner Bvf Inc/il , and other: See Explanation of Responses Biotechnology Value Fund Ii Lp .

Five Prime Therapeutics Inc (FPRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Five Prime Therapeutics Inc (FPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Five Prime Therapeutics Inc (FPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Five Prime Therapeutics Inc (FPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Five Prime Therapeutics Inc Insider Transactions

No Available Data

Biotechnology Value Fund L P Mailing Address

Above is the net worth, insider trading, and ownership report for Biotechnology Value Fund L P. You might contact Biotechnology Value Fund L P via mailing address: 44 Montgomery Street, 40th Fl, San Francisco Ca 94104.